alendronate has been researched along with piperidines in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Black, EC; Bryant, HU; Chandrasekhar, S; Frolik, CA; Magee, DE | 1 |
| Bemis, K; Bryant, HU; Burr, DB; Helterbrand, J; Higgs, R; Iversen, P; Owan, I; Sato, M; Smietana, F; Takano, Y; Turner, CH | 1 |
| Zaidi, M | 1 |
| Meier, CA | 1 |
| Tonino, RP | 1 |
| Robb-Nicholson, C | 1 |
| Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB | 1 |
| Ullom-Minnich, P | 1 |
| Kleerekoper, M | 1 |
| Chapman, B | 1 |
| Crovella, S; De Leo, L; Decorti, G; Marcuzzi, A; Pontillo, A; Tommasini, A | 1 |
| Marcuzzi, A; Melloni, E; Rimondi, E; Secchiero, P; Tommasini, A; Valencic, E | 1 |
2 review(s) available for alendronate and piperidines
| Article | Year |
|---|---|
Ultrasound and alendronate: new tools for osteoporosis screening and treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcium; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Prognosis; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography; Vitamin D | 1998 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Vitamin D | 1999 |
10 other study(ies) available for alendronate and piperidines
| Article | Year |
|---|---|
Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Topics: Alendronate; Amino Acids; Animals; Biomarkers; Body Weight; Bone Resorption; Cholesterol; Disease Models, Animal; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Organ Size; Osteoporosis, Postmenopausal; Ovariectomy; Piperidines; Radioimmunoassay; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tamoxifen; Uterus | 1996 |
Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone and Bones; Estrogens; Female; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Uterus | 1996 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Role of novel antiresorptive agents for the prevention and treatment of osteoporosis.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
I am 51 years old, perimenopausal, have irritable bowel syndrome and a family history of breast cancer, and am told my bones are thinning. These conditions would seem to rule out my use of estrogen or Fosamax. I weight train and take 1,500 mg of calcium a
Topics: Alendronate; Colonic Diseases, Functional; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Life Expectancy; Lipids; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity | 1999 |
Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium; Decision Trees; Dietary Supplements; Estrogen Replacement Therapy; Estrogens; Exercise; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Risk Factors; Smoking Cessation; Vitamin D | 1999 |
Biochemical bone markers.
Topics: Alendronate; Biomarkers; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Lipids; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1999 |
The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Topics: Acyclic Monoterpenes; Alendronate; Animals; Anti-Inflammatory Agents; Cell Line; Child; Child, Preschool; Cholesterol; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Inflammation Mediators; Lovastatin; Male; Mevalonate Kinase Deficiency; Mice; Monocytes; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Polyenes; Polyisoprenyl Phosphates; Polyunsaturated Alkamides; Pyridines; Quinolones; Terpenes | 2011 |
Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Apoptosis; Autophagy; Biosynthetic Pathways; Cell Death; Cell Shape; Farnesyl-Diphosphate Farnesyltransferase; Inflammation; Interleukin-6; Lipopolysaccharides; Macrophages; Mevalonate Kinase Deficiency; Mevalonic Acid; Mice; Mitochondria; Oxazepines; Piperidines; RAW 264.7 Cells; Tumor Necrosis Factor-alpha | 2021 |